OncoGenex Pharmaceuticals

Type: Company

Name: OncoGenex Pharmaceuticals

First reported 21 hours ago - Updated 20 hours ago - 3 reports

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

BOTHELL, Wash.Despite the availability of drugs that improve survival in patients with cancer, treatment failure attributed to resistance continues to be a major problem in medical oncology.1,2,3,4 Across multiple tumor types, the majority of patients ... [Published Bio-Medicine - 20 hours ago]

Entities: OncoGenex Pharmaceuticals, Cancer, Phase III, Scott Cormack, OGX-427

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Phase II

Update on iCo Therapeutics (ICO)

Many of you who have been following iCo Therapeutics (V.ICO) are likely aware that the stock price has pulled back significantly from where we were 4-5 months ago. The key factors contributing to the pullback are: a lack of news-flow, the recently closed ... [Published StockHouse USA - May 21 2013]

Entities: iCo Therapeutics Inc, Phase II, Phase I

First reported May 13 2013 - Updated May 13 2013 - 1 reports

OncoGenex Pharmaceuticals initiates Phase II bladder cancer trial

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, has initiated the Borealis-2 clinical trial, an investigator-sponsored, randomized Phase II trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder ... [Published Individual.com - May 13 2013]

Entities: Bladder Cancer, OGX-427, OncoGenex Pharmaceuticals, docetaxel

First reported May 06 2013 - Updated May 06 2013 - 1 reports

OncoGenex Pharmaceuticals Price Target Raised to $19.00 at RBC Capital (OGXI)

Investment analysts at RBC Capital increased their target price on shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI)Shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI) traded up 2.15% during mid-day trading on Monday, hitting $10.44. OncoGenex Pharmaceuticals ... [Published American Banking News - May 06 2013]

Entities: OncoGenex Pharmaceuticals, RBC Capital Markets, Investment Analysts, Moving Average

First reported May 06 2013 - Updated May 06 2013 - 1 reports

OncoGenex Loss Lower than Expected - Analyst Blog

OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported first quarter 2013 net loss per share of 46 cents, narrower than the Zacks Consensus Estimate of a loss of 68 cents and the year-ago loss of 67 cents per share.First quarter 2013 revenues were $5.1 million, ... [Published Nasdaq - May 06 2013]

Entities: OncoGenex Pharmaceuticals, OGX-427, Metastatic, non-small cell lung cancer

First reported May 04 2013 - Updated May 04 2013 - 1 reports

OncoGenex Pharmaceuticals PT Raised to $25.00 (OGXI)

Investment analysts at Bloom Burton boosted their target price on shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI)Shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI) traded up 7.35% during mid-day trading on Friday, hitting $10.22. OncoGenex Pharmaceuticals ... [Published American Banking News - May 04 2013]

Entities: OncoGenex Pharmaceuticals, Investment Analysts, Moving Average

First reported May 02 2013 - Updated May 03 2013 - 2 reports

OncoGenex Pharmaceuticals Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

/PRNewswire via COMTEX/ -- OncoGenex Pharmaceuticals, Inc. /quotes/zigman/111981/quotes/nls/ogxi OGXI +1.38% today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter ... [Published BioSpace - May 03 2013]

Entities: OncoGenex Pharmaceuticals, OGX-427, Comtex

First reported May 02 2013 - Updated May 03 2013 - 7 reports

OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript

OncoGenex Pharmaceuticals, Inc. (OGXI) Q1 2013 Earnings Call May 2, 2013 4:30 PM ETOperatorGood afternoon, ladies and gentlemen, and welcome to the OncoGenex Update on Clinical Development Programs and Discussion of First Quarter 2013 Financial Results ... [Published Seeking Alpha - May 03 2013]

Entities: OGX-427, OncoGenex Pharmaceuticals, Phase II, Killer Whale, Scott Cormack

First reported May 03 2013 - Updated May 03 2013 - 1 reports

OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript

OncoGenex Pharmaceuticals, Inc. ( OGXI ) Q1 2013 Earnings Call May 2, 2013 4:30 PM ET Executives Susan Specht – Director, IR Scott Cormack – President and CEO Cindy Jacobs – EVP and CFO Susan Wyrick – Senior Director Finance and Principal ... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 03 2013]

Entities: OncoGenex Pharmaceuticals, Scott Cormack, Leerink Swann & Co Inc, William Blair

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Shares of OncoGenex Pharmaceutical Under Pressure, Down 3.0%

(Financial News Network On) OncoGenex Pharmaceutical (NASDAQ:OGXI) is a company whose shares are active, trading 3.0% lower to $9.83. The S&P is trading lower by 0.4% to 1,591 and the Dow is trading 0.4% lower to 14,777. There is potential upside of ... [Published Individual.com - May 01 2013]

Entities: OncoGenex Pharmaceuticals, Standard & Poor's

First reported Apr 30 2013 - Updated May 01 2013 - 7 reports

OncoGenex (OGXI) to Initiate OGX-427 Phase 2 in Combo with ABRAXANE

OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced plans for the initiation of the Rainier trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE (paclitaxel protein-bound particles ... [Published Street Insider - May 01 2013]

Entities: OGX-427, Abraxane, OncoGenex Pharmaceuticals

First reported May 01 2013 - Updated May 01 2013 - 1 reports

OncoGenex Sets Date to Webcast Discussion of Clinical Development Program and 1st Quarter 2013 Financial Results

OncoGenex Pharmaceuticals, Inc. announced that the Company's first quarter 2013 financial results will be released on May 2, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon.According to a release, management ... [Published Individual.com - May 01 2013]

Entities: OncoGenex Pharmaceuticals, Investor Relations, Cancer, Patient, Canada

Quotes

...Ormiston. "In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2 percent. The Promus PREMIER Stent System truly is a major step forward in stent technology."

Boston Scientific Announces Results from Promus Premier; Salix's Budesonide Foam Shows Significan ... [Published BioMedReports - 5 hours ago]

"At this year's ASCO we're highlighting the breadth and depth of our clinical development programs, which evaluate innovative therapies that target important mechanisms of cancer treatment resistance in a variety of cancers" said Scott Cormack

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [Published Bio-Medicine - 20 hours ago]

...of cancer treatment resistance in a variety of cancers," said Scott Cormack, President and Chief Executive Officer, OncoGenex Pharmaceuticals Inc. "With three Phase 3 trials for custirsen ongoing and multiple Phase 2 trials for OGX-427 underway, our development programs have never been stronger."

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [Published Morningstar.com - 21 hours ago]

...stated Noah M Hahn MD, Associate Professor of Medicine at Indiana University Simon Cancer Center and one of the primary investigators on the trial. "We hope that this trial will shed new light on the role of Hsp27 in bladder cancer and the ability of OGX-427 to work synergistically with second- or third-line chemotherapy to overcome resistance and prolong survival."

OncoGenex Pharmaceuticals initiates Phase II bladder cancer trial [Published Individual.com - May 13 2013]

More Content

sort by: Date \| Relevance
Boston Scientific Announces Results from Promus... [Published BioMedReports - 5 hours ago]
OncoGenex Announces Multiple 'Trials in Progres... [Published Bio-Medicine - 20 hours ago]
OncoGenex Announces Multiple 'Trials in Progres... [Published Stockwatch - 21 hours ago]
OncoGenex Announces Multiple 'Trials in Progres... [Published Morningstar.com - 21 hours ago]
OncoGenex Announces Multiple 'Trials in Progres... [Published PR Newswire: Health - 21 hours ago]
Update on iCo Therapeutics (ICO) [Published StockHouse USA - May 21 2013]
Isis Pharmaceuticals' Management Presents at UB... [Published Seeking Alpha - May 20 2013]
ISIS Pharmaceuticals Management Presents at Ban... [Published Seeking Alpha - May 15 2013]
OncoGenex Pharmaceuticals initiates Phase II bl... [Published Individual.com - May 13 2013]
OncoGenex to initiate Phase II metastatic pancr... [Published Individual.com - May 10 2013]
OncoGenex Announces that the Borealis-2 Clinica... [Published NewsRX - May 10 2013]
OncoGenex Pharmaceuticals Price Target Raised t... [Published American Banking News - May 06 2013]
OncoGenex Loss Lower than Expected - Analyst Blog [Published Nasdaq - May 06 2013]
OncoGenex Pharmaceuticals PT Raised to $25.00 (... [Published American Banking News - May 04 2013]
OncoGenex Pharmaceuticals Inc. Provides Clinica... [Published BioSpace - May 03 2013]
OncoGenex Pharmaceuticals' CEO Discusses Q1 201... [Published Seeking Alpha - May 03 2013]
OncoGenex Pharmaceuticals' CEO Discusses Q1 201... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 03 2013]
OncoGenex to begin Rainier clinical trial evalu... [Published PharmaBiz - May 03 2013]
AVEO Spurned, ARNA Bleeds, It's Thumbs Up For A... [Published RTTNews.com - May 03 2013]
Delcath Confirms FDA Panel Voted 16-0 Against M... [Published Equities.com - May 03 2013]
Delcath Confirms FDA Panel Voted 16-0 Against M... [Published BioMedReports - May 03 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published WTNZ - May 02 2013]
OncoGenex Pharmaceuticals Provides Clinical Dev... [Published Equities.com - May 02 2013]
8-K - ONCOGENEX PHARMACEUTICALS, INC. (00009498... [Published SEC Filings - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Bio-Medicine - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Yahoo! Finance - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published StockHouse USA - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published Canada NewsWire - May 02 2013]
OncoGenex Pharmaceuticals, Inc. Provides Clinic... [Published PR Newswire: Health - May 02 2013]
Shares of OGXI Down 19.1% Since Downtrend Call ... [Published Individual.com - May 02 2013]

sort by: Date \| Relevance
OncoGenex to begin Spruce clinical trial to eva... [Published PBR - News - Apr 12 2013] OncoGenex is planning to begin the Spruce clinical trial to assess OGX-427 in combination with chemotherapy in treatment of naive patients with advanced non-squamous non-small cell lung cancer (NSCLC). ...
4 Healthcare Stock Stories for Mid-Week Wellness [Published Wall St. Cheat Sheet - Feb 13 2013] Amarin Corporation ( NASDAQ:AMRN ): Current price $8.56 Amarin reported Tuesday that the United States Patent and Trademark Office has published notification for Patent Application Serial Number 13/614,129, which includes claims intended to protect ...
InPlay from Briefing.com [Published MaritimeSecurity.Asia - Feb 13 2013] 7:02 pm Limoneira announces the annexation of East Area 1 into the city of Santa Paula ( LMNR ) : Co announced that on February 12, 2013, East Area 1 was formally annexed into Santa Paula. The annexation was the final required step to enable Limoneira ...